Cullinan Therapeutics (CGEM) Research & Development (2021 - 2023)
Historic Research & Development for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $34.8 million.
- Cullinan Therapeutics' Research & Development rose 6344.45% to $34.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $148.2 million, marking a year-over-year increase of 6113.02%. This contributed to the annual value of $142.9 million for FY2024, which is 354.56% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Research & Development of $34.8 million as of Q4 2023, which was up 6344.45% from $33.8 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Research & Development registered a high of $52.1 million during Q1 2023, and its lowest value of $11.8 million during Q2 2021.
- Moreover, its 3-year median value for Research & Development was $22.9 million (2022), whereas its average is $24.8 million.
- Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Research & Development was 12424.01% (2022), while the steepest drop was 212.19% (2022).
- Cullinan Therapeutics' Research & Development (Quarter) stood at $20.9 million in 2021, then grew by 2.12% to $21.3 million in 2022, then surged by 63.44% to $34.8 million in 2023.
- Its last three reported values are $34.8 million in Q4 2023, $33.8 million for Q3 2023, and $27.4 million during Q2 2023.